pixel
Become A Provider

Vivos Therapeutics Rebrands Proprietary Clinical Protocol for Treating Patients with Breathing and Sleep Disorders

News

The Vivos Method’s Proprietary Combination of Multidisciplinary Protocols and Oral Appliances Featured on New Corporate Website

HIGHLANDS RANCH

Colorado, March 03, 2022

(GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring, today announced a rebranding of its proprietary offering of clinical treatment devices, modalities and protocols, now called The Vivos Method, to better capture the multiple ways in which Vivos can help independent dentists treat their patients.

The Vivos Method uses proprietary clinical protocols with customized oral appliances as part of a multidisciplinary treatment modality that is prescribed by Vivos-trained dentists and medical professionals to help patients suffering from OSA. Unlike current standard-of-care intervention, such as CPAP machines (which require lifetime use) or invasive surgical procedures, patients undergo treatment with The Vivos Method for approximately 12 to 24 months, with potentially significant and lasting airway improvement.

“Our clinical results continue to show the benefits of The Vivos Method, particularly as we enhance and further understand the use and benefits of our multidisciplinary protocols and devices in patients,” said Kirk Huntsman, Vivos Chairman and CEO. “We used to call our offering the Vivos System, but we believe that didn’t do justice to the many options and methods we provide for practitioners to treat their patients suffering from these debilitating conditions. Our rebrand makes it clearer and easier for providers and patients to understand our offerings and the manner in which each can contribute to addressing dentofacial and airway anomalies in a relatable and more approachable way and to feel secure in proactively asking their dentists or medical providers about The Vivos Method.”

To learn more about The Vivos Method, patients can visit the Company’s updated website www.vivos.com to find:

  • Information about OSA and its corresponding symptoms
  • Testimonials from Vivos-trained dentists and their patient’s success stories
  • Opportunities for Vivos partnerships, FAQs and more

In addition to simplifying information for patients visiting the new Vivos site, the Company now provides dentists looking to tackle OSA and sleep therapies guidance in becoming a Vivos Integrated Provider. This turnkey program enables dentists to elevate patient services and care, while also increasing the growth potential for practice revenue and income.

Cautionary Note Regarding Forward-Looking Statements

This press release and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, particularly with respect to the public offering described herein. Words such as “aim,” “may,” “could,” “expects,” “projects,” “intends,” “plans,” “believes,” “predicts,” “anticipates,” “hopes,” “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including, without limitation, the anticipated benefits of Australian regulatory approval described here on the Company’s sales and ability to obtain regulatory approvals in other countries) may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Vivos Investor Relations Contact:

Julie Gannon
Investor Relations Officer
720-442-8113
[email protected]

Vivos Media Relations Contact:

Amy Cook
Public Relations Officer
949-813-0182
[email protected]